Comparative Pharmacology
Head-to-head clinical analysis: SYNOPHYLATE versus THEOBID JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNOPHYLATE versus THEOBID JR.
SYNOPHYLATE vs THEOBID JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular cAMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator